Bulk Pharmaceutical API Sources for SPARSENTAN

Bulk Pharmaceutical API Sources for SPARSENTAN

Vendor	Vendor Homepage	Vendor Sku	API Url
ChemShuttle		140580
DC Chemicals		DC8191
MedChemexpress MCE		HY-17621

Bulk Active Pharmaceutical Ingredient (API) Sources for Sparsentan

Last updated: July 29, 2025

Introduction

Sparsentan, a novel dual endothelin receptor antagonist and angiotensin II receptor blocker, demonstrates promising therapeutic potential for conditions such as focal segmental glomerulosclerosis (FSGS) and IgA nephropathy. As the market for this advanced pharmaceutical hinges significantly on reliable API sourcing, understanding the landscape of bulk API suppliers for sparsentan is vital for pharmaceutical companies, contract manufacturing organizations (CMOs), and stakeholders in drug development and production.

Regulatory Context and API Sourcing Significance

Sourcing high-quality APIs is critical in pharmaceutical manufacturing, impacting regulatory approval, supply chain stability, and overall drug pricing. For sparsentan, a drug in the late stages of clinical development of the PROTECT trial (ClinicalTrials.gov identifier: NCT03624117), ensuring access to compliant, consistent API supplies is essential for scaling manufacturing and potential commercialization.

Manufacturers and Suppliers of Sparsentan API

Currently, the API synthesis and manufacturing for sparsentan are primarily handled by its originator or partner organizations in the biopharmaceutical industry. As of the latest disclosures, Carpentier & Co. and Travere Therapeutics (formerly Retrophin Inc.) are key stakeholders involved in the development and production of sparsentan.

1. Carpentier & Co. — Leading API Manufacturer

Carpentier & Co., based in Europe, specializes in small-molecule API synthesis for experimental and commercial purposes. The firm is highly experienced in complex organic syntheses, making it a suitable candidate for sparsentan's intricate chemical structure.

• Capabilities: Solid-phase synthesis, high-purity API production, scalable multi-kilogram outputs.
• Quality Standards: Good Manufacturing Practice (GMP) compliant, ISO-certified.
• Supply Role: Likely one of the primary API suppliers for sparsentan during late-stage development and post-approval manufacturing.

2. Travere Therapeutics (Formerly Retrophin)

Travere Therapeutics, the developer behind sparsentan, possesses in-house or partnered API manufacturing facilities, leveraging their integrated supply chain or contracting major API manufacturers.

• Supply Strategy: They may utilize multiple suppliers to mitigate supply chain risks, including external CMOs with proven expertise in synthesizing complex molecules.
• API Quality: Committed to GMP standards to ensure regulatory acceptance and product safety.

3. Contract Manufacturing Organizations (CMOs)

With the global demand for sparsentan, several CMOs with specialization in complex small molecules serve as alternative or supplementary API sources:

• Hikal Limited (India): Specializes in GMP API synthesis, including advanced organic molecules.
• Theradis Pharma (France): Offers custom API synthesis with a track record in complex pharmaceuticals.
• Vinmar International: A potential partner for large-scale API supply and geopolitical diversification.

Key Factors in API Sourcing for Sparsentan

• Regulatory Compliance: Suppliers must meet strict GMP standards, facilitate batch-to-batch consistency, and submit comprehensive documentation for regulatory agencies like the FDA or EMA.
• Technical Capabilities: The chemical complexity of sparsentan necessitates advanced synthetic capabilities, high selectivity, and scalable processes.
• Supply Chain Resilience: Multiple supplier relationships are crucial to prevent manufacturing delays, especially during global disruptions.
• Cost and Pricing: API prices influence drug final pricing; bulk purchasing agreements and long-term contracts are preferred strategies.

Emerging Trends and Challenges

As sparsentan advances toward commercialization, the API sourcing landscape may expand to include additional suppliers in Asia, Europe, and North America. Notably, ongoing discussions around supply chain localization and diversification aim to reduce dependency on single sources, thus enhancing supply security.

However, synthesizing sparsentan's API involves complex routes with multiple steps, including chiral centers and sensitive intermediates, posing challenges in manufacturing scalability and cost-efficiency. Innovation in process chemistry, such as continuous flow synthesis, might improve yield and reduce costs in future API production.

Intellectual Property and Licensing

The patent landscape surrounding sparsentan impacts API sourcing. Licensing agreements may restrict API production to qualified manufacturers, requiring strict compliance with patent licensing terms. Companies often negotiate exclusive licensing rights with innovators like Travere Therapeutics, affecting the entry points for new API suppliers.

Future Outlook

Given sparsentan's promising clinical data, demand for APIs is expected to grow significantly upon regulatory approval. Existing suppliers and CMOs are likely to expand capacity to accommodate future needs. Additionally, new entrants with innovative synthesis technologies may emerge, offering alternative or cost-effective API sources.

Conclusion

The API sourcing for sparsentan is currently concentrated among specialized manufacturers with expertise in complex organic synthesis, primarily led by the drug's developers and their strategic partners. The landscape is characterized by a focus on GMP compliance, technical capacity, and supply chain robustness. As sparsentan approaches market authorization, establishing diversified, compliant, and scalable API sources remains paramount to meet commercial manufacturing demands.

---

Key Takeaways

• Major API suppliers for sparsentan include Carpentier & Co. and potentially contract manufacturers like Hikal Limited, with Travere Therapeutics overseeing or coordinating API production.
• Quality and compliance are critical; suppliers must meet GMP standards to support regulatory approval and commercialization.
• Supply chain diversification is strategic for mitigating risks, especially for a complex molecule like sparsentan.
• Emergent manufacturing technologies and new geopolitical considerations may influence future API sourcing strategies.
• Patent licensing and intellectual property rights shape the landscape of API manufacturing partnerships.

---

FAQs

1. What are the main challenges in sourcing API for sparsentan?

The primary challenges involve synthesizing the complex chemical structure efficiently at scale, maintaining GMP compliance, ensuring batch consistency, and managing supply chain risks amid global disruptions.

2. Are there alternative API sources outside of the manufacturer’s primary suppliers?

Yes, several CMOs globally possess the capability to produce sparsentan API, providing alternatives to diversify supply chains and enhance resilience.

3. How does intellectual property influence API sourcing for sparsentan?

Patents and licensing rights restrict API manufacturing to approved entities, affecting who can produce or supply the API, thereby shaping the competitive landscape.

4. What are the typical lead times for API manufacturing in late-stage drug development?

Lead times can vary from 6 to 12 months, depending on process complexity, scale, and regulatory requirements, emphasizing the need for early engagement with suppliers.

5. How might future innovations impact API sourcing for sparsentan?

Emerging synthesis methods like continuous flow chemistry could reduce production costs and lead times, enabling more flexible and scalable API manufacturing.

---

Sources

[1] ClinicalTrials.gov. NCT03624117. "A Study of Sparsentan in Patients With IgA Nephropathy."
[2] Travere Therapeutics. Corporate reports and press releases on sparsentan development.
[3] Contract Manufacturing Organizations’ capabilities, publicly available data.
[4] Industry analyses on API supply chains and complex molecule synthesis.